Related News

Home » Metro » Health and Science

Diabetes profiling link-up

CHINA'S National Center for Drug Screening in Shanghai announced today a collaboration with the US-based PerkinElmer, Inc. to advance personalized medicine and drug profiling for diabetes patients in China.

Scientists will validate new diagnostics for Asian populations through utilizing next generation sequencing technologies.

Once optimized, the technology platform will be able to disseminate its knowledge to hospitals and testing laboratories throughout China.

"We will test all known biomarkers of diabetes to select special diabetes-related biomarkers in Chinese patients," said Wang Mingwei, director of the National Center for Drug Screening.

Several biomarkers have been established in Western populations as predictive markers for drug efficacy.

These are used to make decisions on treatments.

But the validation of these markers has been primarily conducted on Caucasian populations and have not yet been validated on the Chinese populations.

"We will do sequencing Chinese patient samples in order to establish genomic information for drug profiling in China," Wang said.

Currently, different Chinese diabetes patients are usually given the same medicines initially.

Some patients have to try different medicines until seeing the effects.

This is not only bad for treatment but also a waste of money and time, say experts.

Individualized medicine is the trend of modern medicine and a smart use of current medicine by the largest extent, say experts.

The United States Food and Drug Administration requires mandatory biomarker tests for 26 approved drugs and recommends biomarker tests for 90 other approved drugs.


Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.

沪公网安备 31010602000204号

Email this to your friend